Published in J Clin Oncol on September 20, 2005
Quality of life after allogeneic hematopoietic cell transplantation. Blood (2009) 2.49
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 2.11
Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. Psychooncology (2009) 1.98
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood (2012) 1.58
Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant (2009) 1.50
Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol (2008) 1.35
Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant (2010) 1.33
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant (2012) 1.28
Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol (2009) 1.19
Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol (2011) 1.17
Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood (2011) 1.16
Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination. Biol Blood Marrow Transplant (2008) 1.11
Quality of life concerns and depression among hematopoietic stem cell transplant survivors. Support Care Cancer (2010) 1.05
The quality of life of adult survivors of childhood hematopoietic cell transplant. Bone Marrow Transplant (2009) 1.05
Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol (2012) 1.01
Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J (2011) 0.99
Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol. Health Qual Life Outcomes (2011) 0.98
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2015) 0.98
Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol (2013) 0.96
Sexual function changes during the 5 years after high-dose treatment and hematopoietic cell transplantation for malignancy, with case-matched controls at 5 years. Blood (2007) 0.96
Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2010) 0.95
Cancer, physical activity, and exercise. Compr Physiol (2012) 0.94
Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transplant (2011) 0.94
Economic survivorship stress is associated with poor health-related quality of life among distressed survivors of hematopoietic stem cell transplantation. Psychooncology (2012) 0.94
Mental status changes after hematopoietic stem cell transplantation. Cancer (2009) 0.94
Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol (2011) 0.93
Sexuality after hematopoietic stem cell transplantation. Cancer J (2009) 0.93
Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life. Bone Marrow Transplant (2013) 0.93
Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation. J Cancer Surviv (2010) 0.92
The effect of pre-transplant distress on immune reconstitution among adult autologous hematopoietic cell transplantation patients. Brain Behav Immun (2012) 0.91
Changes in nutritional status, body composition, quality of life, and physical activity levels of cancer patients undergoing autologous peripheral blood stem cell transplantation. Support Care Cancer (2013) 0.91
Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation. J Cancer Surviv (2010) 0.90
Cardiovascular disease in survivors of hematopoietic cell transplantation. Cancer (2013) 0.90
Development and implementation of an Internet-based survivorship care program for cancer survivors treated with hematopoietic stem cell transplantation. J Cancer Surviv (2011) 0.87
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter (2012) 0.86
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther (2012) 0.86
Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2009) 0.84
Marital adjustment, satisfaction and dissolution among hematopoietic stem cell transplant patients and spouses: a prospective, five-year longitudinal investigation. Psychooncology (2010) 0.83
Financial impact of allogeneic hematopoietic cell transplantation on patients and families over 2 years: results from a multicenter pilot study. Bone Marrow Transplant (2016) 0.82
Factors associated with poor general health after stem-cell transplantation. Support Care Cancer (2007) 0.82
Differences in health behaviour between recipients of allogeneic haematopoietic SCT and the general population: a matched control study. Bone Marrow Transplant (2014) 0.82
Distress, problems and supportive care needs of patients treated with auto- or allo-SCT. Bone Marrow Transplant (2013) 0.80
Quality of life (QOL), supportive care, and spirituality in hematopoietic stem cell transplant (HSCT) patients. Support Care Cancer (2012) 0.80
Late effects and healthcare needs of survivors of allogeneic stem cell transplantation: a qualitative study. BMJ Support Palliat Care (2012) 0.80
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report. Biol Blood Marrow Transplant (2016) 0.79
Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplant (2015) 0.78
Measuring social activities and social function in long-term cancer survivors who received hematopoietic stem cell transplantation. Psychooncology (2010) 0.78
Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management. Biol Blood Marrow Transplant (2014) 0.78
Patients' goals related to health and function in the first 13 months after allogeneic stem cell transplantation. Support Care Cancer (2011) 0.77
Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2016) 0.76
Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant (2015) 0.76
Quality of life in Arab Muslim cancer survivors following hematopoietic stem cell transplantation: comparison with matched healthy group. Support Care Cancer (2015) 0.76
Developing a Risk Prediction Model for Long-Term Physical and Psychological Functioning after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant (2015) 0.75
Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Crit Rev Oncol Hematol (2015) 0.75
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. Clin Investig (Lond) (2013) 0.75
Sexual function 1-year after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2016) 0.75
Importance of functional evaluation after hematopoietic cell transplantation. Rev Bras Hematol Hemoter (2012) 0.75
Cardiovascular Complications of Hematopoietic Stem Cell Transplantation. Curr Treat Options Cardiovasc Med (2016) 0.75
Determining best methods to screen for religious/spiritual distress. Support Care Cancer (2016) 0.75
Long-term effects and psychological adjustment: study protocol of a large register-based study on quality of life among survivors of hematological malignancies. BMC Cancer (2017) 0.75
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med (2003) 3.57
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood (2003) 3.16
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol (2008) 2.99
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood (2004) 2.77
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol (2007) 2.66
Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA (2004) 2.65
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.49
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood (2007) 2.49
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood (2009) 2.44
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol (2005) 2.41
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst (2003) 2.29
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood (2004) 2.28
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood (2013) 2.23
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood (2012) 2.19
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant (2008) 2.15
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol (2010) 2.07
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol (2005) 2.04
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood (2003) 2.01
A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood (2012) 2.00
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant (2008) 1.96
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood (2006) 1.95
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood (2013) 1.94
A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med (2006) 1.91
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood (2011) 1.90
Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood (2012) 1.88
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol (2010) 1.84
MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med (2007) 1.83
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood (2002) 1.80
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant (2008) 1.75
Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood (2003) 1.72
Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain (2008) 1.69
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest (2014) 1.66
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 1.65
Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol (2006) 1.63
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant (2013) 1.62
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood (2003) 1.59
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood (2008) 1.59
Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 1.56
Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant (2006) 1.54
Cognitive-behavioral therapy for children with functional abdominal pain and their parents decreases pain and other symptoms. Am J Gastroenterol (2010) 1.54
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol (2013) 1.53
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood (2007) 1.52
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant (2013) 1.51
Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology (2011) 1.50
Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest (2002) 1.49
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant (2006) 1.47
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood (2002) 1.45
Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood (2011) 1.41
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet (2009) 1.40
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood (2003) 1.35
Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol (2005) 1.35
Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control (2003) 1.32
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood (2003) 1.29
Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis (2006) 1.29
Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2007) 1.28
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2010) 1.25
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood (2009) 1.25
Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol (2011) 1.24
Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med (2011) 1.23
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2005) 1.23
Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood (2012) 1.22
A comparison of maintenance-tailored therapy (MTT) and standard behavior therapy (SBT) for the treatment of obesity. Prev Med (2009) 1.21
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood (2009) 1.19
Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood (2004) 1.19
Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood (2013) 1.18